

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE ON THE LICENSED-IN OF BREDININ FROM ASAHI KASEI PHARMA CORPORATION

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 15 June 2021, the Group had successfully entered into an license agreement with Asahi Kasei Pharma Corporation (“**AKP**”), an Japan-based company, pursuant to which the Group is awarded the exclusive license to commercialise Bredinin™ (generic name: mizoribine) for the indication of suppression of rejection reaction in renal transplantation in Mainland China. Bredinin™ was first launch in China in 1999 and has already established a decent market presence within the patient population. In addition, supplemental new drug application (“**sNDA**”) for the additional indications such as lupus nephritis (“**LN**”) and nephrotic syndrome (“**NS**”) were submitted to China’s National Medical Products Administration in June 2020.

ABOUT BREDININ™

Bredinin™ (Mizoribine) is an imidazole nucleoside and an immunosuppressive agent and has been used in suppression of rejection reaction in renal transplantation. Mizoribine has less adverse effects than mycophenolate mofetil , another immunosuppressant used for some of the same diseases. Mizoribine has also been approved in Japan for the treatment of LN (1990), rheumatoid arthritis (1992), and primary NS (1995), and in these diseases, it has often been used in combination with corticosteroids and/or anti-inflammatory drugs.

* For identification purpose only

ABOUT ASAHI KASEI PHARMA CORPORATION

In accordance with the Asahi Kasei Group Mission of “Contributing to life and living for people around the world”, AKP operates pharmaceutical and diagnostic businesses in the Health Care Business Unit of the Asahi Kasei Group. AKP has developed numerous innovative drugs in the field of orthopedics, acute care, neurology (including pain), and immunology, contributing to society by providing such products to patients who suffer from diseases. More information at www.asahikasei-pharma.co.jp/en/.

ABOUT LEE’S PHARM

Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics and urology, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information at www.leespharm.com.

By order of the Board
Lee’s Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 21 June 2021

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors, Dr. Li Xiaoyi and Mr. Simon Miles Ball are non-executive Directors, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.